
Control - Vehicle
Isotype controls
bsAb1
RMPI-14
bsAb1 + RPMI
Tumor Volume (mm3)
4000
3500
3000
2500
2000
1500
1000
500
0
-500
-1000
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40
Days post implantation

Figure 1


Tumor Volume (mm³)
200
150
100
50
0
PBS
Isotype controls
RPMI-14
bsAb1
bsAb1 + RPMI-14
bsAb1 + RPMI-14
bsAb1 + RPMI-14

Figure 2


Tumor Volume (mm3)
2000
1500
1000
500
0
0
5
10
15
20
25
Days post implantation
***
****
Control - Vehicle
Isotype controls
RPMI
bsAb1
bsAb1+RPMI-14 – same-time dosing
bsAb1+RPMI-14 – RPMI-14, then bsAb1
bsAb1+RPMI-14 – bsAb1, then RPMI-14

Figure 3


REGN2810
B-cell Dose Escalation
May open in parallel
REGN2810 B-cell Expansion cohorts
Indolent NHL; N= 20
Aggressive NHL; N= 20
HL; N= 20
Combo Dose Escalation in B-NHL
Combo Expansion in B-NHL
Indolent NHL; N= 20
Aggressive NHL; N= 20

Figure 4


bsAb1 Dose Escalation in ALL
bsAb1 Expansion cohorts in ALL
• R/R ALL; N= 20 each
• MRD+ ALL; N= 20 each
May open in parallel
Combo Dose Escalation in ALL
Combo Expansion cohorts in ALL
• R/R ALL; N= 20 each
• MRD+ ALL; N= 20 each
bsAb1 Cohort DL1
bsAb1 Cohort DL2
bsAb1 Cohort DL3
bsAb1 Cohort DL4
DE criteria met
DE criteria met for both single agent & combination treatment**
Combination : DL1
Combination : DL2
Initiate combination therapy when DE criteria met AND PD criteria met*
DE: Dose Escalation
PD: pharmacodynamic

Figure 5


TREATMENT PERIOD
FOLLOW-UP
BL/Screen
-28 Days
REGN2810 Q2W X 12 doses
(up to 24) doses
6 months
5
12
24
36
48
30d post
LD; wk 27
or 51**
Q12W
6-12 month treatment period
**Depending on 6 or 12
month of treatment
Tumor Imaging; LN biopsy (at baseline and if progression suspected); BMA/BMBx, (at
baseline and repeat(s) if positive at screening and if progression suspected)
LN biopsy [research]
Tumor imaging and Optional BMA/BMBx, LN biopsy (SOC or as clinically indicated)

Figure 6


INDUCTION
CONSOLIDATION
FOLLOW-UP
BL/ Screen -28 Days
bsAb1 QW X 11 doses
bsAb1 Q4W X 6 doses
6 months
WEEKS
1 2 3 4 5 6 7 8 9 10 11 13 17 21 25 29 33
30d post LD; Q12W or wk 37
9 Month Treatment Period
6 Months
BMA/BMBx (smear, flow, cytogenetics, MRD assessment)
Lumbar puncture, with IT chemotherapy
Optional (SOC) BMA/BMBx
bsAb1 Treatment

Figure 7


BL/
Screen
-28 Days
INDUCTION
bsAb1 QW X 11 doses
CONSOLIDATION
bsAb1 Q4W X 6 doses
REGN2810 Q2W X 12 (up to 24) doses
FOLLOW-UP
6 months
30d post
last dose
Q12W
6 Months
9-12 month treatment period
Tumor Imaging; LN biopsy (at baseline and if progression suspected); BMA/BMBx, at baseline and repeat(s) Q12 Weeks (if positive at screening or if progression suspected)
LN biopsy after 4 weeks of treatment [research]
Tumor imaging and Optional BMA/BMBx, LN biopsy (SOC or as clinically indicated)

Figure 8


INDUCTION
CONSOLIDATION
FOLLOW-UP
BL/
Screen
-28 Days
bsAb1 QW X 11 doses
bsAb1 Q4W X 6 doses
REGN2810 Q2W X 12 (up to 24) doses
6 months
30d post
last dose
Q12W
6 Months
9-12 Month Treatment Period
BMA/BMBx (smear, flow, cytogenetics, MRD assessment)-at end of 4 weeks of treatment, week 12 and Q12W theraafter
Lumbar puncture Q12W, with IT chemotherapy
Optional (SOC) BMA/BMBx

Figure 9